DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Epratuzumab is an investigational drug.
There have been 26 clinical trials for Epratuzumab. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2010.
The most common disease conditions in clinical trials are Lupus Erythematosus, Systemic, Lymphoma, and Leukemia, Lymphoid. The leading clinical trial sponsors are Immunomedics, Inc., UCB Pharma, and Nantes University Hospital.
There are fifty-three US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Epratuzumab
|Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL||Nantes University Hospital||Phase 2|
|Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia||Immunomedics, Inc.||Phase 1/Phase 2|
|Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia||Institut Cancerologie de l'Ouest||Phase 1/Phase 2|
Top disease conditions for Epratuzumab
Top clinical trial sponsors for Epratuzumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Epratuzumab||Start Trial||Trilayer coated pharmaceutical packaging||SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL)||Start Trial|
|Epratuzumab||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|Epratuzumab||Start Trial||Chimeric receptors and uses thereof in immune therapy||National University of Singapore (Singapore, SG) St. Jude Children's Research Hospital (Memphis, TN) Unum Therapeutics Inc. (Cambridge, MA)||Start Trial|
|Epratuzumab||Start Trial||Targeting of innate immune response to tumor site||GAVISH-GALILEE BIO APPLICATIONS, LTD. (Kiryat Shmona, IL) HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (Jerusalem, IL)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|